INCLINE VILLAGE, Nev. - The Northern Nevada/Lake Tahoe affiliation of the Pancreatic Cancer Action Network, the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure, applauds community leaders in Incline Village and Crystal Bay for IVGID Resolution Number 1813 recognizing November 2012 as National Pancreatic Cancer Awareness Month.The Resolution echoes similar proclamations throughout Nevada and the Nation at all levels of government. Incline Village residents Stuart and Ginnie Jed thank the IVGID Board for their resolution."Survivors and caregivers, families and friends affected by this disease would like to thank the leaders in our community for recognizing November as National Pancreatic Cancer Awareness Month," stated Ginnie Jed, Northern Nevada/Lake Tahoe Volunteer Community Representative of the Pancreatic Cancer Action Network. "With the continued support we will work towards increasing federal funding and local awareness for this terrible disease."Stuart Jed, a 4-year survivor of Stage IV Pancreatic Cancer, encouraged all to become proactive if they find themselves experiencing lingering undiagnosed stomach issues."There is presently no means of early detection such as a scan or blood test, and the early symptoms of pancreatic cancer can often be vague stomach issues. Ask the question of your health care provider," he urged.Pancreatic cancer is the fourth leading cause of cancer death in the United States. Despite improved survival rates for many other forms of cancer, pancreatic cancer remains the only major cancer that still has a five-year relative survival rate in the single digits at 6 percent. The incidents and death rate for pancreatic cancer are increasing, and pancreatic cancer is anticipated to move from the fourth to the second leading cause of cancer death in the U.S. by 2020, and possibly as early 2015.Currently, research dedicated to pancreatic cancer receives approximately two percent of the federal dollars awarded by the NCI and there is no long-term and comprehensive strategy in place to improve survival.The Recalcitrant Cancer Research Act (H.R. 733), formerly the Pancreatic Cancer Research & Education Act, will ensure that the NCI develops a comprehensive scientific framework for developing early diagnostics and treatment options that will increase the survival rate for pancreatic cancer and other recalcitrant cancer patients.The bill was introduced in the Senate by Senator Sheldon Whitehouse (D-RI) and in the House by Representatives Anna Eshoo (D-CA) and Leonard Lance (R-NJ), and after receiving broad bipartisan support, it was passed by the U.S. House of Representatives on September 19, 2012. It is essential that we make research into pancreatic cancer a priority until real progress is made.